CCWM
IMVT icon

Cassaday & Co Wealth Management’s Immunovant IMVT Stock Holding History

Cassaday & Co Wealth Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347 Hold
9
– – ﹤0.01% 1166
2026
Q1 		$224 Buy
+9
New +$233 ﹤0.01% 1257

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cassaday & Co Wealth Management's IMVT Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Immunovant (IMVT) position steady in Q2 2026 at 9 shares worth $347. The position accounts for ﹤0.01% of the portfolio, ranked #1166.

Cassaday & Co Wealth Management first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Cassaday & Co Wealth Management held 9 shares of Immunovant worth $347 as of Q2 2026.
  • Cassaday & Co Wealth Management left its Immunovant share count unchanged in Q2 2026.
  • Immunovant made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1166 holding.
  • Cassaday & Co Wealth Management first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.